Key insights
- A 10% owner of Sensei Biotherapeutics sold approximately $500k in stock, despite recent positive news including the initiation of a Phase 1b/2 trial for its breast cancer therapy and optimistic analyst ratings. While the company has a strong cash position, it is also burning through cash rapidly. The insider selling, even with positive developments, introduces a bearish signal for the stock.
James Peyer, a ten percent owner of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), sold shares of the company’s common stock totaling $500,542 on June 1, 2026, according to a recent Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock has surged nearly 19% over the past week, trading at $19.79.
The transactions involved two separate sales of common stock. In the first transaction, Peyer disposed of 24,524 shares. These shares were sold at a weighted average price of $20.00 per share, with individual sale prices ranging from $20.00 to $21.00.
A second transaction on the same day saw Peyer sell an additional 476 shares of Sensei Biotherapeutics common stock. These shares were sold at a price of $21.14 per share.According to InvestingPro analysis, the stock appears undervalued at current levels, with the company holding more cash than debt on its balance sheet. However, InvestingPro Tips indicate the company is quickly burning through cash—one of 13 exclusive tips available to subscribers.
Cumulatively, James Peyer sold a total of 25,000 shares of Sensei Biotherapeutics common stock, with prices for the sales ranging from $20.00 to $21.14 per share. Following these transactions, Peyer directly owns 130,142 shares of Sensei Biotherapeutics common stock.
In other recent news, Sensei Biotherapeutics has announced the initiation of a Phase 1b/2 trial for its investigational therapy PIKTOR in patients with HR+/HER2- advanced breast cancer. The trial marks a significant step for the company following its acquisition of Faeth Therapeutics, which brought PIKTOR into its portfolio. This therapy, a combination of serabelisib and sapanisertib, targets multiple nodes of the PI3K/AKT/mTOR pathway. Meanwhile, analysts from Lucid Capital Markets and Leerink Partners have both initiated coverage on Sensei Biotherapeutics with optimistic outlooks. Lucid Capital Markets rated the stock as a Buy, while Leerink Partners gave it an Outperform rating, both setting a price target of $50.00. These ratings suggest a positive view from analysts regarding the company’s prospects. Sensei Biotherapeutics’ ongoing developments and analyst endorsements reflect growing interest in its therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates SNSE alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if SNSE is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?